Business
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
ChromaDex announces supply agreement with Designs for Health, offering new Niagen®-formulated products LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp.
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nChromaDex announces supply agreement with Designs for Health, offering new Niagen®-formulated products\n\n LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s extensive healthcare practitioner (HCP) network.\n\n“We are happy to be working with a science-based company like Designs for Health to bring Niagen® to healthcare practitioners and their patients,” said Rob Fried, CEO of ChromaDex. “These practitioners play a pivotal role in educating consumers on the importance of NAD+ and providing science-backed health solutions.”\n\nThe Niagen® inclusive formulas will be available to healthcare practitioners through the Designs for Health network of customers throughout the United States, Canada, and Australia.\n\n“ChromaDex has been leading the industry with NAD+ research and we have long admired their approach to creating high quality products as we believe in developing health products without compromise to support wellness for all. We are extremely excited to collaborate with them now and in the future,” said Jonathan Lizotte, CEO of Designs for Health.\n\nFor additional information about ChromaDex, please visit www.chromadex.com.\n\nAbout ChromaDex:\n\nChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.\n\nForward-Looking Statements:\n\nThis release contains forward-looking statements within the meaning of Sect...